 Multiple chemotherapeutic agents including cisplatin, doxorubicin HCL, paclitaxel, carboplatin, and oral etoposide, alone and in combination, have been studied for persistent, advanced or recurrent endometrial cancer. A phase III study by the Gynecologic Oncology Group GOG compared doxorubicin with and without cisplatin GOG 107 for patients with advanced or recurrent endometrial cancer. A higher response rate 45 vs. 27 was noted for combination therapy and has been considered by many to be the standard chemotherapy regimen for treatment of patients with advanced endometrial cancer. However, clinical trials have continued to define the optimal chemotherapy regimen for this disease. Recently, the use of whole abdominal radiation therapy in the adjuvant setting for advanced endometrial cancer was demonstrated to be inferior to the combination of cisplatin and doxorubicin. The predicted 2-year survival of 70 for patients receiving the chemotherapeutic regimen was superior to patients that received radiation therapy 59p0.01. 